

Express Mail Label No.: EV 317 172 250 US
Date: February 10, 2004

Docket No.: VPI/00-130-07 DIV US

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

APPLICANTS: Bebbington, et al.
DIVISIONAL OF: 10/034,019 EXAMINER: Tamthom Ngo Truong
FILING DATE: Herewith ART UNIT: 1624
FOR: PYRAZOLE COMPOUNDS USEFUL AS PROTEIN KINASE INHIBITORS

February 10, 2004
Cambridge, Massachusetts

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Pursuant to the duty of disclosure under 37 C.F.R. §§1.56, 1.97 and 1.98, applicants hereby make of record the documents listed below and on the attached modified Form PTO-1449 (submitted in duplicate) in the above-identified application. The order of presentation of the references should not be construed as an indication of the importance of the references.

This Information Disclosure Statement is being filed:

- ☐ within three months of the filing date of the National Application;
- ☐ within three months of the filing date of the entry of the National Stage, as set forth in 37 C.F.R. §1.491, in an International Application; or
- ☒ before the mailing date of a first Office Action on the merits in the above-identified case.

Accordingly, no fee or certification is required. (37 C.F.R. §1.97).


A copy of the references are enclosed unless otherwise indicated on the attached Form PTO-1449 (modified). It is respectfully requested that the Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims, and signs the enclosed form PTO-1449 to evidence that the

APPLICANTS: **Bebbington, et al.**
U.S.S.N.: **Not Yet Assigned**

By submitting this Information Disclosure Statement, the Applicant makes no representation that: (1) a search has been performed, of the extent of any search performed, or that more relevant information does not exist; (2) the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 C.F.R. §1.56(b); and (3) the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 U.S.C. §102.

Notwithstanding any statements by the Applicant, the Examiner is urged to form his/her own conclusion regarding the relevance of the cited information. An early and favorable action is hereby requested. Please charge any additional fees that may be due, or credit any overpayment of same, to Deposit Account No. 50-0725, Reference No. VPI/00-130-07 DIV US.

Respectfully submitted,



Andrea L.C. Robidoux, Reg. No. 47,902
Agent for Applicants
c/o Vertex Pharmaceuticals Incorporated
 130 Waverly Street
 Cambridge, Massachusetts 02139
 Tel: (617) 444-6731
 Fax: (617) 444-6483

Modified Form 1449/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)	Application Number	Not Yet Assigned
	Filing Date	February 10, 2004
	First Named Inventor	David Bebbington
	Group Art Unit	16124
	Examiner Name	Tamthom Ngo Truong
	Attorney Docket Number	VPI/00-130-07 DIV US

U.S. PATENT DOCUMENTS							
Exam Initials	Cite No.	U.S. Patent Document No.	Issue Date	Name of Patentee(s) or Applicant(s)	Class	Sub Class	Filing Date If Appropriate
	A1*	5,710,158	20-Jan-1998	Rhone-Poulenc Rorer Pharmaceuticals Inc.			

FOREIGN PATENT DOCUMENTS							
Exam Initials	Cite No.	Foreign Patent Document		Name of Patentee(s) or Applicant(s)	Date of Publication	Translation	
		Office	Number			Yes	No
	B1*		WO 01/25220	Kinetix Pharmaceuticals Inc.	12-Apr-2001		
	B2*		WO 00/78757	Shionogi Bioresearch Corp.	28-Dec-2000		
	B3*		WO 00/39101	Astrazeneca UK Limited	06-Jul-2000		
	B4*		WO 00/21955	Zeneca Limited	20-Apr-2000		
	B5*		WO 02/18346	Pfizer Products Inc.	07-Mar-2002		

OTHER NON PATENT LITERATURE DOCUMENTS		
Exam Initials	Cite No.	Name of Author, Title (when appropriate), Publication, Volume, Page(s), Date, Etc.

* a copy of this reference is not provided as it was previously cited by or submitted to the office in a prior application, U.S.S.N. 10/034,019, filed December 20, 2001, and relied upon for an earlier filing date under 35 U.S.C. §120 (continuation, continuation-in-part, and divisional applications).

Examiner Signature		Date Considered	
--------------------	--	-----------------	--